T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines.
Pothast CR, Hofsink Q, Haggenburg S, Dijkland RC, Van de Meent M, Van Dijk K, Bhoekhan MS, Haverkate NJE, Van Meerloo J, Falkenburg JHF, De Groen RAL, Broers AEC, Van Doesum JA, Van Binnendijk RS, Den Hartog G, Lissenberg-Witte BI, Kater AP, Smits GP, Wouters D, Van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Van Baarle D, De Vries RD, Van Meerten T, Mutsaers PGNJ, Goorhuis A, Nijhof IS, Hazenberg MD, Heemskerk MHM, Rutten CE; COBRA KAI study team.
Pothast CR, et al.
Haematologica. 2025 May 29. doi: 10.3324/haematol.2024.287136. Online ahead of print.
Haematologica. 2025.
PMID: 40438989
Free article.